Abstract
Crucial event in the metastasis of cancer cells is the secretion of matrix metalloproteinases (MMPs), which are responsible for the degradation of extracellular matrix (ECM). Among them, matrix metalloproteinase-2 (MMP-2) is a gelatinase, which degrades basement membrane type-IV collagen. Immunohistochemistry was performed to detect MMP-2 protein in 135 infiltrative breast carcinomas. MMP-2 was studied along with clinicopathological parameters (tumor size, histological type, nuclear and histological grade, stage, lymph node status, ER, and PR), patients' survival and tissue inhibitor metalloproteinase-2 (TIMP-2), Ki-67, and p53 proteins. MMP-2 immunoreactivity was detected in the cytoplasm in cancer cells in 102 (75.6%) and in both tumor and tumor stromal cells in 37 (27.4%) of 135 cases respectively. MMP-2 reactivity in cancer cells displayed a statistically significant association with tumor size > 2 cm (p = 0.022). In tumor stromal cells a strong parallel association was observed between the expression of MMP-2 and TIMP-2 (p = 0.015), while an inverse correlation was found between MMP-2 and both Ki-67 and p53 (p = 0.033 and p = 0.034 respectively). In the subgroup with negative lymph nodes MMP-2 was also inversely associated with p53 in cancer cells (p = 0.045). Finally a statistically significant association was revealed using Kaplan–Meier and Cox's proportional hazard regression model between the MMP-2/TIMP-2 phenotype and patients' better survival (p = 0.021). Our results point out the strong relation between MMP-2 and TIMP-2 and the effect of the MMP-2/TIMP-2 phenotype in the patients' overall survival. The inverse correlation between MMP-2 and both Ki-67 and p53 can be explained by the potential inhibition of MMP-2 by TIMP-2. These results suggest the necessity of further investigation.
Similar content being viewed by others
References
Liotta LA, Tryggvason K, Garbisa S, Hart J, Foltz CM, Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980
Afzal S, Lalani EN, Foulkes WD, Boyce B, Tickle S, Cardillo MR, Baker T, Pignatelli M, Stamp WHG: Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab Invest 74: 406-421, 1996
Bir Kedal-Hansen H, Moore WGI, Booden MK, Windsor LJ, Bir Kedal-Hansen B, DeCarlo A, Engler JA: Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4: 197-250, 1993
Corcoran ML, Hewitt RE, Kleiner Jr DE, Stetler-Stevenson WG: MMP-2: expression, activation and inhibition. Enzyme Protein 49: 7-19, 1996
Strogin AY, Collier JE, Krasnov PA, Genrich LT, Marmer BL, Goldberg GI: Human 92 kDa type IV collagenase: functional analysis of fibronectin and carboxyl-end domains. Kidney Int 43: 158-162, 1993
Stetler-Stevenson WG, Aznavoorian S, Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9: 541-573, 1993
Rha SY, Yang WI, Kim JH, Roh JK, Min JS, Lee KS, Kim BS, Chung HC: Different expression patterns of MMP-2 and MMP-9 in breast cancer. Oncol Rep 5: 875-879, 1998
Brown PD, Levy AT, Margulies IM, Liotta LA, Stetler-Stevenson WG: Independent expression and cellular processing of Mr 72000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res 50: 6184-6191, 1990f
Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370: 61-65, 1994
Takino T, Hiroshi S, Yamamoto E, Seiki M: Cloning of a human gene potentially encoding a novel matrix metalloproteinase having a C-terminal transmembrane domain. Gene 155: 293-298, 1994
Emmet-Buck MR, Emonard HP, Corcoran ML, Krutsch HC, Foidart J-M, Stetler-Stevenson WG. Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2 complex. FEBS Lett 364: 28-32, 1995
Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72-kDa type IV collagenase. J Biol Chem 270: 5331-5338, 1995
Polette M, Birembaut P: Matrix metalloproteinases in breast carcinoma. Breast J 2: 209-220, 1996
Giiles C, Polette M, Piette J, Munaut C, Thompson EW, Birembaut P, Foidart JM: High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int J Cancer 65: 209-213, 1996
Nomura H, Sato H, Seiki M, Mai M, Okada Y: Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 55: 3263-3266, 1995
Hoyhtya M, Fridman R, Komarek D, Porter JK, Stetler-Stevenson WG, Liotta LA, Liang CM: Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer 56: 500-505, 1994
Levy AT, Cioce V, Sobel ME, Gerbisa S, Grigioni WF, Liotta LA, Stetler-Stevenson WG: Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 51: 439-444, 1991
Toi M, Ishigaki S, Tominaga T: Metalloproteinases and tissue inhibitors of metalloproteinases. Breast Cancer Res Treat 952: 113-124, 1998
Hanriet P, Blavier L, Declerck YA: Tissue inhibitors of metalloproteinases (TIMPs) in invasion and proliferation APMIS 107: 111-119, 1999
Nagase H, Woessner JF: Matrix metalloproteinases. J Biol Chem 274: 21,491-21,494, 1999
Liotta LA, Stetler-Stevenson WG: Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51: 5054-5059, 1991
Talvensaari-Mattila A, Pããkkö P, Turpeenniemi-Hujanen T: MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Breast Cancer Res Treat 58: 287-293, 1999
WHO: Histological typing of breast tumors. In: Hartman WH, Uzello L, Sobin LH, Stalsberg H (eds) International Histological Classification of Tumours. 2nd edn, World Health Organization, Geneva, 1981, pp 15-25
Robins P, Pinder S, De Klerk N: Histological grading of breast carcinomas: a study of interobserved agreement. Hum Pathol 28: 873-879, 1995
Association of Directors of Anatomic and Surgical Pathology: Recommendations for life reporting of breast carcinoma. Hum Pathol 27: 220-224, 1996
Kinne DW: Staging and follow-up of breast cancer patients. Cancer 67: 1196-1198, 1991
Hsu SM, Raine L, Fanger H: The use of avidin-biotin-peroxidase complex (ABC) in the immunoperoxidase technique: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577-580, 1981
Talvensaari-Mattila A, Paãkko P, Hoythya M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein. Cancer 83: 1153-1162, 1998
Matrisian LM, McDonnell S, Miller DB, Navre M, Seftor EA, Hendrix MJ: The role of matrix metalloproteinase stromelysin in the progression of squamous cell carcinomas. Am J Med Sci 302: 157-162, 1991
Naylor MS, Stamp GWH, Daview B, Balkwill FR: Expression and activity of MMPs and their regulators in ovarian cancer. Int J Cancer 58: 50-56, 1994
Pouslom R, Pignatelli M, Stetler-Stevenson WG, Liotta L, Wright P, Jeffrey R, Longcroft J, Rogers L, Stamp GWH: Stromal expression of 72 kDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. J Pathol 1675: 150A, 1992
Têtu B, Brisson J, Lapointe H, Bernard P: Prognostic signifi-cance of stromelysin 3, gelatinase A and urokinase expression in breast cancer. Hum Pathol 29: 979-985, 1998
Afzal S, Lalani E-N, Baker T, Bayce B, Docherty A, Pignatelli M, Stamp GWH: Membrane localization of activated gelatinase in adenocarcinomas. J Pathol 172: 101A, 1994
Emonard HP, Remacle AG, Noel AC, Grimand JA, Stetler-Stevenson WG, Foidart JM: Tumor cell surface-associated binding site for the Mr 72,000 type IV collagenase. Cancer Res 52: 5845-5848, 1992
Baramova, Foidart JM: Matrix metalloproteinase family. Cell Biol Int 19: 239-242, 1995
Kleiner Jr D, Unsworth EJ, Krutzsch HC, Stetler-Stevenson WG: Higher order complex formation between the 72-kilodalton type IV collagenase and tissue inhibitor of metalloproteinase-2. Biochemistry 31: 1665-1672, 1992
Menashi S, Dehem M, Souliac I, Legrand Y, Fridman R: Density-dependent regulation of cell-surface association of matrix metalloproteinase-2 (MMP-2) in breast-carcinoma cells. Int J Cancer 75: 259-265, 1998
Remacle AG, Noël A, Duggan C, Dermott E, O'Higgins N, Fiodart JM, Duffy MJ: Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Brit J Cancer 77(6): 926-931, 1998
Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, De Clerk YA, Mundy GR: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. Clin Invest 99: 2509-2517, 1997
Sledge WGM, Qulali R, Goulet EA, Bone, Fife R: Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 87: 1546-1550, 1995
Onisto M, Riccio MP, Scannapieco P, Caenazzo CR, Griggio L, Spina M, Stetler-Stevenson WG, Garbisa S: Gelatinase A/TIMP-2 imbalance in lymph node positive breast carcinomas, as measured by RT-PCR. Int J Cancer 63: 623-626, 1995
Visscher DW, Hoyhtya M, Ottosen SK et al.: Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence.Int J Cancer 59: 339-344, 1994
Sato H, Takono T, Kinoshita T, Imai K, Okada Y, Stetler-Stevenson WG, Seiki M: Cell-surface binding and activation of gelatinase A induced by expression of membrane-type 1 matrix metalloproteinase (MT1-MMP). FEBS Lett 385: 238-240, 1996
Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Gakiopoulou H, Dimopoulos MA: The prevalence of bcl-2, p53 and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol 29: 146-154, 1998
Alessandro R, Minafra S, Minafra IP, Onisto M, Garbisa S, Melchiori A, Tetlow L, Woolley DE: Metalloproteinase and TIMP expression by the human breast carcinoma cell line 8701-BC. Int J Cancer 55: 250-255, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nakopoulou, L., Tsirmpa, I., Alexandrou, P. et al. MMP-2 Protein in Invasive Breast Cancer and the Impact of MMP-2/TIMP-2 Phenotype on Overall Survival. Breast Cancer Res Treat 77, 145–155 (2003). https://doi.org/10.1023/A:1021371028777
Issue Date:
DOI: https://doi.org/10.1023/A:1021371028777